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The triple drug combination consisting of irinotecan, oxaliplatin and 5-fluorouracil (FOLFOXIRI) has demonstrated higher activity and
efficacy compared to the doublet FOLFIRI. 5-Fluorouracil could be substituted in FOLFOXIRI regimen by capecitabine, an oral
fluoropyrimidine with similar efficacy. Recently, a dose-finding trial has demonstrated the feasibility of the combination of irinotecan,
oxaliplatin and capecitabine (XELOXIRI) and established their recommended doses. The aim of this study was to evaluate the activity
of XELOXIRI. A total of 36 patients with unresectable metastatic colorectal cancer received irinotecan 165mgm
 2 and oxaliplatin
85mgm
 2 on day 1 plus capecitabine 2000mgm
 2 per day orally in two doses from day 1 to day 7, every 2 weeks. Grade 3–4
toxicities were infrequent, expect for neutropenia and diarrhoea, which were each observed in 30% of patients. Two complete and
twenty-two partial responses were obtained, corresponding to an overall response rate of 67% (95% CI 51.4–82%). After a median
follow-up of 17.7 months, the median progression-free and overall survival were 10.1 and 17.9 months, respectively.
The substitution of 5-fluorouracil with capecitabine, in combination with irinotecan and oxaliplatin, is feasible and does not impair the
activity of the regimen. However, the XELOXIRI combination is associated with a high incidence of diarrhoea and, therefore, should
be considered as a not preferable alternative to FOLFOXIRI.
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In the past decade, the advent of oxaliplatin and irinotecan has led
to changes in the first-line treatment of metastatic colorectal
cancer (mCRC; Saunders and Iveson, 2006). In fact, the combina-
tion of one of these new cytotoxic drugs with 5-fluorouracil (5-FU)
and leucovorin (LV) significantly increases tumour response and
prolongs survival of patients with unresectable advanced colorectal
cancer over 5-FU/LV alone (Punt, 2004). Moreover, a pooled
analysis of seven phase III trials comparing 5-FU/LV plus
irinotecan or oxaliplatin containing doublets vs 5-FU alone
demonstrated that survival of mCRC patients might be improved
administrating all the three active drugs in the course of the
disease. However, in a sequential strategy, 20–50% of patients who
progress after first-line chemotherapy cannot receive second-line
treatment, mainly because of deterioration of their performance
status and liver function (Grothey et al, 2004). Furthermore,
another pooled analysis indicated that there is a strong correlation
between the response rate to first-line chemotherapy and the
possibility of a postchemotherapy radical resection of metastases
that may be associated with long-term survival (Folprecht et al,
2005).
Keeping these concepts in mind, the GONO group developed in
phases I and II trials a triple-drug combination of oxaliplatin,
irinotecan and 5-FU/LV named FOLFOXIRI (Falcone et al, 2002;
Masi et al, 2004) and compared this combination to a standard
doublet combination of 5-FU/LV plus irinotecan (FOLFIRI) in a
phase III study on 244 mCRC patients (Falcone et al, 2007). The
treatment with first-line FOLFOXIRI was feasible, associated with
manageable toxicities and obtained a higher tumour response rate
and a higher postchemotherapy radical resection of metastases
rate. FOLFOXIRI also significantly increased progression-free
survival (PFS) and overall survival over FOLFIRI.
For its activity, the triple-drug combination should be preferred
especially if response rate is the major goal of treatment, whereas
in other situations sequential therapy could be a useful alternative
(Koopman et al, 2007).
Capecitabine is an oral fluoropyrimidine prodrug that achieves
tumour-selective generation of 5-FU through conversion by the
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sthymidine phosporylase enzyme that is more active in CRC cells
compared with healthy tissue (Walko and Lindley, 2005). Different
phase III trials have shown that capecitabine is at least as active
and effective as 5-FU in the first-line treatment of mCRC, with a
superior safety profile (Hoff et al, 2001; Van Cutsem et al, 2001;
Cassidy et al, 2002). Moreover, the use of capecitabine instead of
5-FU, either with irinotecan or oxaliplatin, confirmed the activity
and efficacy of the drug (Cassidy et al, 2004; Koopman et al, 2007).
Based on these results, the triple combination of capecitabine with
oxaliplatin and irinotecan appears to be an interesting regimen to
be studied in mCRC patients that could simplify the treatment
delivery and reduce the complications related to the central venous
catheter compared to infusional 5-FU, as used in the FOLFOXIRI
regimen.
Different schedules of capecitabine emerged from phase I trials
(Budman et al, 1998; Mackean et al, 1998). It is worth noting that
mathematical methods applied to the definition of the ideal
treatment schedule suggested that the optimal duration of
treatment with capecitabine is 7 days and predicted that drug
delivery beyond 7 days could contribute to toxicity, with
diminishing anticancer benefit (Traina et al, 2008). Moreover, a
randomised phase II trial conducted by Scheithauer et al.
demonstrated that a dose-intensified bimonthly combination of
oxaliplatin plus capecitabine administered for 7 days followed by 7
days of rest is as safe and feasible as the combination of oxaliplatin
on day 1 with capecitabine administered from day 1 to day 14
every 3 weeks, with higher RR and PFS for the bimonthly regimen
(Scheithauer et al, 2003).
On these bases, the GONO performed a phase I trial in mCRC
patients to establish the recommended dose of capecitabine in
combination with fixed doses of irinotecan and oxaliplatin
(XELOXIRI), administered at the same doses of the GONO-
FOLFOXIRI regimen (Fornaro et al, 2009). The study demon-
strated the feasibility of XELOXIRI at the recommended dose of
capecitabine 2.000mgm
 2 per day on days 1–7 in combination
with oxaliplatin 85mgm
 2 and irinotecan 165mgm
 2 on day 1,
repeated every 2 weeks, but has also pointed out a large
interpatient variability on the tolerance and on the pharmaco-
kinetic values of the drugs. For these reasons, we decided that
XELOXIRI should be evaluated in a phase II trial on a larger
number of patients. In this study, we report the results of the phase
II study with the XELOXIRI combination as the first-line treatment
of unresectable metastatic colorectal cancer patients.
MATERIALS AND METHODS
Patients selection
Main eligibility criteria included histologically confirmed diag-
nosis of colorectal adenocarcinoma with unresectable metastatic
disease; measurable disease according to Response Evaluation
Criteria in Solid Tumors (RECIST) criteria; age 18–75 years; ECOG
performance status (PS) o2 for patients aged p70 years and
ECOG PS¼0 for patients aged 470 years; adequate bone marrow
reserve (leukocyte count X3.500 per mm
3, neutrophil count
41.500 per mm
3, platelet count X100.000 per mm
3); adequate
kidney and liver functions (serum creatinine p1.3mg per 100ml,
serum bilirubin o1.5mg per 100ml, and aspartate amino-
transferase, alanine aminotransferase and alkaline phosphatase
o2.5 upper normal values (o5 upper normal values if liver
metastases were present)). Previous fluoropyrimidine-based ad-
juvant chemotherapy was allowed, if ended more than 6 months
before enrolment. Main exclusion criteria were previous palliative
chemotherapy for metastatic disease; previous chemotherapy
including irinotecan or oxaliplatin; symptomatic cardiac disease
or myocardial infarction in the past 24 months or uncontrolled
arrhythmia; active infections; inflammatory bowel disease; total
colectomy. The study was conducted in accordance to the Helsinki
declaration and to the Good Clinical Practice guidelines. Patients
provided their written informed consent before registration. The
protocol was approved by the ethics committees of all participating
institutions.
Treatment
The chemotherapy regimen consisted of irinotecan 165mgm
 2 i.v.
in 250ml of NaCl 0.9% over 1h, followed immediately by
oxaliplatin 85mgm
 2 i.v. in 250ml dextrose 5%, as used in the
FOLFOXIRI regimen. Capecitabine was administered at the dose of
2000mgm
 2 per day orally in two divided doses from day 1 to day
7 (Figure 1). Treatment was repeated every 2 weeks and
administered until evidence of disease progression, unacceptable
toxicity, patient refusal or for a maximum of 12 cycles. Toxicities
were graded according to the National Cancer Institute Common
Terminology Criteria (NCI CTC) version 3.0. Treatment was
delayed until recovery in case of neutrophils o1.000 per mm
3,
platelets o100.000 per mm
3 or diarrhoea or stomatitis grade 41
on the planned day of treatment. In the case of peripheral
neurotoxicity grade 42, oxaliplatin was interrupted. In the case of
previous dose-limiting toxic effects, treatment was continued after
resolution of the event with doses of oxaliplatin, irinotecan and
capecitabine reduced by 25%, except in the case of grade 3–4
diarrhoea, when only irinotecan and capecitabine doses were
reduced by 25%. In the case of life-threatening toxic effects,
treatment was definitively interrupted or continued at doses
reduced by 50%. To prevent nausea and vomiting, 5-hydroxy-
tryptamine-3 receptor antagonists þ dexamethasone 16mg were
administered i.v. before chemotherapy, and repeated as i.m.
injections at standard doses in the 2 following days. Atropine
0.25mg subcutaneously was given to treat cholinergic syndrome,
and repeated as prophylaxis of future events in the following
cycles. Loperamide 2mg, orally every 2h, and oral rehydration
were prescribed in case of delayed diarrhoea. No prophylactic
treatment with white blood cell growth factors for neutropenia was
recommended.
Evaluation criteria
Pretreatment evaluation included medical history and physical
examination, ECOG PS assessment, complete blood cell counts
with differential, complete blood profile, carcinoembryonic anti-
gen (CEA), electrocardiogram, chest and abdominal tomography
(CT) scan and any other appropriate diagnostic procedure to
evaluate metastatic sites. During treatment, a physical examination
and a complete blood cell count, AST, ALT, total bilirubin and
creatinine were performed every 2 weeks. Evaluation of tumour
Irinotecan
mg m–2
Oxaliplatin
mg m–2
Capecitabine
mg m–2 day–1
165
1-h IV
85
2-h IV
2000
PO
Day 1
Repeated every 2 weeks 
XELOXIRI
Days 2 → 7 
Figure 1 XELOXIRI regimen: treatment schedule. IV, intravenous;
PO, per os
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sresponse was performed with CT scan every 8 weeks according to
the standard RECIST criteria (Therasse et al, 2000). The best
overall response for each patient was reported. All results were
reviewed by an independent radiologist and had to be confirmed
28 days or more after initial documentation of the response. The
overall response rate was calculated according to the intention-to-
treat analysis. Progression-free survival was calculated from the
day of registration to the date of first observation of clinical and/or
radiological evidence of progression or death, whichever occurred
first. Overall survival (OS) was calculated from the day of
registration to the date of death or last contact. OS and PFS were
estimated using the Kaplan–Meier method.
Statistical analysis
The minimax two-stage sequential design described by Simon
(1989) was used to determine the number of patients to be
included. As responses with standard reference combinations of
irinotecan þ capecitabine or oxaliplatin þ capecitabine are
observed in about 40–50% of patients, a response rate X70% for a
new regimen that has acceptable toxic effects would be considered
promising. Therefore, the design parameters p0 (response rate in
null hypothesis) and p1 (response rate in alternative hypothesis)
selected were 0.50 and 0.70, respectively. Also considering an a and
b error probability of 0.05 and 0.20, respectively, the first stage of
the study required 23 patients, and if at least 13 objective responses
were observed, 13 additional patients had to be enrolled in the
second stage of the study. The regimen was considered interesting
for further investigation if X24 objective responses out of 36
evaluable patients were observed.
RESULTS
Patient characteristics
From February 2006 through March 2007, a total of 36 patients
with unresectable metastatic colorectal cancer were enrolled. The
baseline patients characteristics are reported in Table 1. Median
age was 65 years (range 42–73); 24 patients (67%) had
synchronous metastases at diagnosis, half of patients had multiple
sites of metastases, 44% had liver involvement X25 and 25% had
received adjuvant treatment before the enrolment into the study.
Toxicity and dose administration
All patients were assessable for safety. A total of 342 cycles of
chemotherapy were administered with a median of 12 cycles per
patient (range 2–12). Overall, the treatment was relatively well
tolerated without frequent grade 3–4 toxicities (Table 2), except
for neutropenia and diarrhoea. Indeed, 8 patients (22%) experi-
enced at least one episode of grade 3 diarrhoea and 3 (8%) of grade
4. Neutropenia of grade 3–4 was observed in 30% of patients, with
febrile neutropenia in 4 cases (11%). Other grade 3–4 toxicities
included nausea in 3% of patients, vomiting in 6%, thrombo-
cytopenia in 8% and peripheral neurotoxicity in 6%. Three
patients were hospitalised for febrile neutropenia and diarrhoea,
and one patient died because of sepsis. One hundred and forty-
three cycles (43%) were administered with a dose reduction of at
least one drug. Most cycles (82%) were administered every 2 weeks
as per protocol, whereas 61 cycles (18%) were delayed, usually
because of toxicity. The median dose intensities of irinotecan,
oxaliplatin and capecitabine calculated during the entire period of
treatment among the 36 patients were 63mgm
 2 per week (76% of
planned), 36mgm
 2 per week (85% of planned) and 4842mgm
 2
per week (69% of planned), respectively. Although the use of
G-CSF was not planned, it was used in five (1.5%) cycles.
Antitumour activity and survival
At an intention-to-treat analysis, we observed 22 (61%) partial and
2 (6%) complete responses, for an overall response rate of 67%
(95% confidence interval 51.4–82%). In addition, nine patients
(25%) achieved a disease stabilisation as best response and only
three patients (8%) progressed. Eight patients underwent surgical
removal and/or radiofrequency ablation of residual metastases
after response to chemotherapy with a radical (R0) resection
performed in 6 (17%) of the 36 initially unresectable patients (38%
among patients with liver involvement only).
After a median follow-up of 17.7 months, with 24 patients who
experienced disease progression and 17 who died, the median
progression-free survival and overall survival were 10.1 (95%
confidence interval 7.4-12-8) and 17.9 (95% confidence interval
13.5–22.5) months, respectively (Figure 2A and B). Twenty-one
patients received a second-line treatment after disease progression,
in most cases containing cetuximab.
DISCUSSION
In the past years, improvements in chemotherapy for the treatment
of metastatic colorectal cancer have resulted in significant benefits
in terms of antitumour activity and efficacy (Punt, 2004; Saunders
and Iveson, 2006). Several studies have suggested that the best
results can be achieved exposing patients to all three main active
cytotoxics (5-FU, irinotecan and oxaliplatin) (Grothey et al, 2004;
Table 1 Patients characteristics
Characteristic Number of patients (%)
Patients 36
Median age (years; range) 65 (42–73)
Sex
Male 28 (78)
Female 8 (22)
ECOG PS
0 32 (89)
1 3 (8)
2 1 (3)
Primary tumour site
Colon 26 (72)
Rectum 10 (28)
Previous surgery on primary tumour 29 (81)
Previous adjuvant chemotherapy 9 (25)
Previous radiotherapy 2 (6)
Number of metastatic sites
Single 18 (50)
Multiple 18 (50)
Timing of metastases
Synchronous 24 (67)
Metachronous 12 (33)
Sites of disease
Liver 29 (81)
Lung 13 (36)
Lymph nodes 10 (28)
Peritoneum 6 (17)
Other 3 (8)
Liver involvement
o25% 20 (56)
25–50% 7 (19)
450% 9 (25)
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sFolprecht et al, 2005). In particular, a phase III study conducted by
the GONO demonstrated the superiority of the first-line triplet
FOLFOXIRI vs a standard doublet in terms of activity and efficacy.
However, 5-FU had to be administered as a 48-h continuous
infusion by a central venous catheter to make the combination
feasible (Falcone et al, 2002, 2007; Masi et al, 2004).
Our report is the first multicenter phase II study evaluating the
activity of a first-line triplet combination of irinotecan and
oxaliplatin associated with capecitabine instead of 5-fluorouracil
in the treatment of metastatic colorectal cancer. The overall
response rate of 67% and the median PFS of 10.1 months are
comparable to those obtained in phases II and III trials with
FOLFOXIRI. Moreover, our results are also comparable to those of
a single-centre phase I–II study recently reported by the ITMO
with the combination of irinotecan 180mgm
 2 on day 1,
oxaliplatin 85mgm
 2 on day 2 and capecitabine 2000mgm
 2
per day from day 2 to day 6 (COI), in 29 mCRC patients (Bajetta
et al, 2007). However, the ITMO COI schedule seems more
complex with a lengthy outpatient 2-day schedule for irinotecan
and oxaliplatin administration.
The major concern with the XELOXIRI regimen is the
gastrointestinal toxicity, in particular in terms of grade 3–4
diarrhoea that was experienced by 30% of patients. The incidence
of severe diarrhoea is apparently higher to that observed in studies
with FOLFOXIRI and also to that reported by Bajetta et al with the
COI regimen, in this case probably because of the lower dose
intensity of capecitabine administered. Also, two recent phase III
trials comparing the combination of irinotecan with 5-fluorouracil
or capecitabine (at the dose of 2000mgm
 2 per day on days 1–14
every 21 days) reported a high (about 40%) rate of grade 3–4
diarrhoea with capecitabine and irinotecan (Fuchs et al, 2007;
Kohne et al, 2008). The incidence of diarrhoea with this
combination may be reduced by slightly lowering the dose of the
two drugs, without impairing the activity (Punt and Koopman,
2008; Reinacher-Schick et al, 2008). Finally, neutropenia was
observed frequently in our study with at least one grade 3–4
episode in 30% of patients, but it was usually short lasting and
rarely complicated, and it did not differ from that obtained with
the infusional 5-FU triplet.
In conclusion, the substitution of capecitabine for infusional
5-fluorouracil, in combination with irinotecan and oxaliplatin,
retained an interesting activity in the first-line treatment of
metastatic colorectal cancer and could replace the need for an
implanted central venous catheter. However, the incidence of
grade 3–4 diarrhoea experienced with the XELOXIRI regimen
seems higher than that with FOLFOXIRI and the regimen with the
oral fluoropyrimidine seemed less manageable than that with
infusional 5-fluorouracil. Therefore, a triple-drug combination of
CPT-11 and L-OHP with capecitabine instead of infusional 5-FU as
we used is not a preferable alternative to FOLFOXIRI, but can be
considered for patients with mCRC refusing or with contra-
indications to the implantation of a central venous catheter.
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